Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice
- Authors
- Kim, Won Jong; Yockman, James W.; Jeong, Ji Hoon; Christensen, Lane V.; Lee, Minhyung; Kim, Yong-Hee; Kim, Sung Wan
- Issue Date
- Sep-2006
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- systemic injection; anti-angiogenesis; tumor therapy; soluble Flt-1; targeted gene delivery
- Citation
- JOURNAL OF CONTROLLED RELEASE, v.114, no.3, pp.381 - 388
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CONTROLLED RELEASE
- Volume
- 114
- Number
- 3
- Start Page
- 381
- End Page
- 388
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/181063
- DOI
- 10.1016/j.jconrel.2006.05.029
- ISSN
- 0168-3659
- Abstract
- Vascular endothelial growth factor (VEGF) is an endogenous mediator of tumor angiogenesis. Blocking associations of the VEGF with its corresponding receptors (Flt-1, KDR/flk-1) have become critical for anti-tumor angiogenesis therapy, Previously, we synthesized PEI-g-PEG-RGD conjugate and evaluated as an angiogenic endothelial polymeric gene carrier. In this study, PEI-g-PEG-RGD/pCMV-sF1t-1 complexes are evaluated in terms of tumor growth inhibition in vivo. Complexes were repeatedly injected systemically via tail vein into subcutaneous tumor-bearing mice. As a result, tumor growth was inhibited in the PEI-g-PEG-RGD/pCN/1V-sFlt-1 injected group. However, this effect was not identified in PEI-g-PEG/pCMVsF1t-1 or PEI-g-PEG-RGD/pCNIV-GFP control groups. Moreover, the survival rate increased in the PEI-g-PEG-RGD/pCMV-sFlt-1 group compared with the controls group. These results suggest that delivery of pCMV-sFIt-1 using PEG-g-PEG-RGD may be effective for anti-angiogenic gene therapy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 공과대학 > 서울 생명공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/181063)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.